{
    "id": "6217dc9d3a8413c65300002d",
    "question": "Is NfL (neurofilament light chain) a biomarker of neurodegeneration?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, let's analyze the given documents and look for any mention of neurofilament light chain (NfL) in relation to neurodegeneration. Neurofilaments are a type of intermediate filament protein that provides strength and stability to long cell processes, such as neurons. Neurofilament light chain (NfL) is a component of neurofilaments. According to Document [5], the overexpression of human NF-L or NF-H in mice results in mice that have an ALS-like disease, suggesting that neurofilaments, including NfL, may play a role in neurodegeneration. However, the documents do not explicitly state that NfL is a biomarker of neurodegeneration. Nonetheless, considering the context of neurofilaments and their involvement in neurodegenerative diseases, we can infer that NfL might be related to neurodegeneration. Let's look for more information about NfL as a biomarker. Document [26] lists neurofilament L (NF-L) as a protein that co-assembles with other neurofilament proteins and is found in neurons. This suggests that NfL is a component of neurons and may be involved in neurodegenerative processes. However, the document does not explicitly state that NfL is a biomarker of neurodegeneration. Considering the information provided, the answer to the question is not explicitly supported by the documents. However, based on the context and the role of neurofilaments in neurodegenerative diseases, it can be inferred that NfL might be related to neurodegeneration. The most accurate answer based on the provided information is not explicitly stated, but based on the context, the best answer choice is B. no, as the documents do not provide clear evidence that NfL is a biomarker of neurodegeneration.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_30545",
            "title": "InternalMed_Harrison",
            "content": "Motor neuropathy with paraprotein Associated with other neurodegenerative disorders ALS, the affected neurons demonstrate ubiquitin-positive aggregates, typically associated with the protein TDP43 (see below). Also seen is proliferation of astroglia and microglia, the inevitable accompaniment of all degenerative processes in the central nervous system (CNS)."
        },
        {
            "id": "Cell_Biology_Alberts_4719",
            "title": "Cell_Biology_Alberts",
            "content": "Members of another family of intermediate filaments, called neurofilaments, are found in high concentrations along the axons of vertebrate neurons (Figure 16\u201370). Three types of neurofilament proteins (NF-L, NF-M, and NF-H) coassemble in vivo, forming heteropolymers. The NF-H and NF-M proteins have lengthy C-terminal tail domains that bind to neighboring filaments, generating aligned arrays with a uniform interfilament spacing. During axonal growth, new neurofilament subunits are incorporated all along the axon in a dynamic process that involves the addition of subunits along the filament length as well as the ends. After an axon has grown and connected with its target cell, the diameter of the axon may increase as much as fivefold. The level of neurofilament gene expression seems to directly control axonal diameter, which in turn influences how fast electrical signals travel down the axon. In addition, neurofilaments provide strength and stability to the long cell processes of"
        },
        {
            "id": "Neurology_Adams_8479",
            "title": "Neurology_Adams",
            "content": "stabilizes their structure, and participates in synaptic plasticity in a yet to be defined manner. In the pathologic circumstances of Alzheimer disease, progressive supranuclear palsy, and one form of frontotemporal dementia (see further on), tau is hyperphosphorylated and aggregates, resulting in paired helical filaments that make up the neurofibrillary tangles. Electrophoretically, tau moves with the \u03b22-globulins and functions as a transferrin, that is, it binds iron and delivers it to the cell. Its concentration can be measured in the CSF and serum, but this has not yet proven clearly to be useful as a diagnostic test or to offer understanding of the pathogenesis of the disease."
        },
        {
            "id": "Neurology_Adams_8471",
            "title": "Neurology_Adams",
            "content": "Three additional microscopic changes give this disease its distinctive character: (1) The presence within the nerve cell cytoplasm of thick, fiber-like strands of silver-staining material, also in the form of loops, coils, or tangled masses (Alzheimer neurofibrillary changes or \u201ctangles\u201d) (Fig. 38-1). These strands are composed of a hyperphosphorylated form of the microtubular protein, tau, and appear as pairs of helical filaments when studied ultrastructurally. (2) Spherical deposits of amorphous material scattered throughout the cerebral cortex and easily seen with periodic acid-Schiff (PAS); the core of the aggregates is the protein amyloid, surrounded by degenerating nerve terminals (neuritic plaques) that stains with silver. Amyloid is also scattered throughout the cerebral cortex in a nascent \u201cdiffuse\u201d form, without organization or core formation and then is appreciated mainly by immunohistochemical methods, as well as deposition in the walls of small blood vessels near the"
        },
        {
            "id": "InternalMed_Harrison_2016",
            "title": "InternalMed_Harrison",
            "content": "The major degenerative dementias include AD, DLB, FTD and related disorders, HD, and prion diseases, including Creutzfeldt-Jakob disease (CJD). These disorders are all associated with the abnormal aggregation of a specific protein: A\u03b242 and tau in AD; \u03b1-synuclein in DLB; tau, TAR DNA-binding protein of 43 kDa (TDP-43), or fused in sarcoma (FUS) in FTD; huntingtin in HD; and misfolded prion protein (PrPsc) in CJD (Table 35-2). APPROACH TO THE PATIENT: Three major issues should be kept at the forefront: (1) What is the best fit for a clinical diagnosis? (2) What component of the dementia syndrome is treatable or reversible? (3) Can the physician help to alleviate the burden on caregivers? A broad overview of the approach to dementia is shown in Table 35-3. The major degenerative dementias can usually be distinguished by the initial symptoms; neuropsychological, neuropsychiatric, and neurologic findings; and neuroimaging features (Table 35-4)."
        },
        {
            "id": "Cell_Biology_Alberts_4721",
            "title": "Cell_Biology_Alberts",
            "content": "The neurodegenerative disease amyotrophic lateral sclerosis (ALS, or Lou Gehrig\u2019s disease) is associated with an accumulation and abnormal assembly of neurofilaments in motor neuron cell bodies and in the axon, aberrations that may interfere with normal axonal transport. The degeneration of the axons leads to muscle weakness and atrophy, which is usually fatal. The overexpression of human NF-L or NF-H in mice results in mice that have an ALS-like disease. However, a causative link between neurofilament pathology and ALS has not been firmly established. basal cell of epidermis"
        },
        {
            "id": "Neurology_Adams_8417",
            "title": "Neurology_Adams",
            "content": "is a question that cannot be answered with certainty; evidence to this effect is largely anecdotal. Instead, these degenerative disease processes, by their very nature, appear to develop de novo, without relation to known antecedent events, and their symptomatic expressions are late events in the pathologic process, occurring only when the degree of neuronal loss exceeds the ability of a system to function at a clinically acceptable level. Irreversibility and steady progression of clinical manifestations when measured over periods of months or years is another feature common to the neurodegenerative conditions. However, several of these diseases sometimes display periods of relative stability."
        },
        {
            "id": "Neurology_Adams_10684",
            "title": "Neurology_Adams",
            "content": "malignant plasma cell dyscrasia. This agrees with our own experience, but other series have found rates of myeloma as high as 75 percent. In any case, 90 percent of primary amyloidosis is the result of a monoclonal protein in the blood (rarely polyclonal). Macrophage enzymes cleave the larger immunoglobulin molecules and the light chains aggregate to form amyloid deposits in tissue, or the plasma cells may produce light chains directly (\u201clight chain disease\u201d). Lambda light chain predominates in the idiopathic variety of amyloidosis and kappa light chain is more common in myeloma. In a few cases, the light chain is found only in the urine (as Bence Jones protein)."
        },
        {
            "id": "InternalMed_Harrison_30258",
            "title": "InternalMed_Harrison",
            "content": "FIGURE 448-5 Neuropathology in frontotemporal lobar degeneration (FTLD). FTLD-tau (A\u2013C) and FTLD-TDP (D\u2013F) account for over 90% of patients with FTLD, and immunohistochemistry reveals characteristic lesions in each of the major histopathologic subtypes within each class: small compact or crescentic neuronal cytoplasmic inclusions and short, then neuropil threads in FTLD-TDP, type A; (E) diffuse/granular neuronal cytoplasmic inclusions (with a relative paucity of neuropil threads) in FTLD-TDP, type B; and (F) long, tortuous dystrophic neurites in FTLD-TDP, type C. TDP can be seen within the nucleus in neurons lacking inclusions but mislocalizes to the cytoplasm and forms inclusions in FTLD-TDP. Immunostains are 3-repeat tau (A), phospho-tau (B and C), and TDP-43 (D\u2013F). Sections are counterstained with hematoxylin. Scale bar applies to all panels and represents 50 \u03bcm in A, B, C, and E and 100 \u03bcm in D and F."
        },
        {
            "id": "InternalMed_Harrison_30247",
            "title": "InternalMed_Harrison",
            "content": "Although early studies suggested that 15\u201330% of patients with FTD showed underlying AD at autopsy, progressive refinement in clinical diagnosis has improved pathologic prediction accuracy, and most patients diagnosed with FTD at a dementia clinic with expertise in FTD will show underlying FTLD pathology. Microscopic findings seen across all patients with FTLD include gliosis, microvacuolation, and neuronal loss, but the disease is subtyped according to the protein composition of neuronal and glial inclusions, which contain either tau or TDP-43 in ~90% of patients, with the remaining ~10% showing inclusions containing FUS (Fig. 448-4)."
        },
        {
            "id": "Neurology_Adams_8582",
            "title": "Neurology_Adams",
            "content": "degeneration) can closely mimic Huntington disease, as described further on; sometimes only the genetic and pathologic findings settle the matter. A midlife progressive chorea without dementia (after more than 25 years of followup) that does not display the Huntington genotype has been reported. In at least one family in which this clinical picture is dominantly inherited, the fundamental defect is a mutation in the gene encoding the light chain of ferritin (Curtis). Affected individuals have axonal changes in the pallidum with swollen, ubiquitinand tau- positive aggregates; serum ferritin levels may be depressed. The implication of this mutation is that perturbations of iron metabolism may be toxic to neurons, a feature that also characterizes Hallervorden-Spatz disease, now called PANK disease, mentioned below."
        },
        {
            "id": "Pathology_Robbins_5205",
            "title": "Pathology_Robbins",
            "content": "Barker RA, Williams-Gray CH: Review: the spectrum of clinical features seen with alpha synuclein pathology, Neuropathol Appl Neurobiol 42(1):6\u201319, 2016. [Aggregation of \u03b1-synuclein marks several neurodegenerative diseases, and this review considers shared and distinct aspects of the pathologic findings.] Colonna M, Wang Y: TREM2 variants: new keys to decipher Alzheimer disease pathogenesis, Nat Rev Neurosci 17(4):201\u2013207, 2016. [One of the strongest links between Alzheimer disease and microglia is the risk associated with variants of TREM2 on the surfaces of microglia.] Ling SC, Polymenidou M, Cleveland DW: Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis, Neuron 79(3):416\u2013438, 2013. [A clear summary of mechanisms associated with neurodegeneration that can be linked to the consequences of altered RNA dynamics within cells and the consequence of this for proteins.] http://ebooksmedicine.net"
        },
        {
            "id": "InternalMed_Harrison_30208",
            "title": "InternalMed_Harrison",
            "content": "At autopsy, the earliest and most severe degeneration is usually found in the medial temporal lobe (entorhinal/perirhinal cortex and hippocampus), lateral temporal cortex, and nucleus basalis of Meynert. The characteristic microscopic findings are neuritic plaques and NFTs (Fig. 448-1). These lesions may accumulate in small numbers during FIGURE 448-1 Neuropathology of Alzheimer\u2019s disease. A. Early neurofibrillary degeneration, consisting of neurofibrillary tangles and neuropil threads, preferentially affects the medial temporal lobes, especially the stellate pyramidal neurons that compose the layer 2 islands of entorhinal cortex, as shown. B. Higher magnification view reveals the fibrillary nature of tangles (arrows) and the complex structure of neuritic plaques (arrowheads), whose major component is A\u03b2 (inset shows immunohistochemistry for A\u03b2). Scale bars are 500 \u03bcM in A, 50 \u03bcM in B, and 20 \u03bcM in B inset."
        },
        {
            "id": "InternalMed_Harrison_30916",
            "title": "InternalMed_Harrison",
            "content": "and neuronal pathology is increasingly recognized as a major contributor to irreversible neurologic disability. Inflammation, demyelination, and plaque formation are also present in the cerebral cortex, and significant axon loss indicating death of neurons is widespread, especially in advanced cases (see \u201cNeurodegeneration,\u201d below)."
        },
        {
            "id": "Neurology_Adams_8731",
            "title": "Neurology_Adams",
            "content": "Many types of inclusions are, of course, nonspecific, as, for example, \u03b1-synuclein\u2013positive inclusions have been detected in several neurodegenerative syndromes. Appropriate control studies to determine whether the glial inclusions are found in nondegenerative lesions in brain (e.g., at the edge of an infarct) are needed. Also lacking is information about the frequency of these cytoplasmic inclusions in relation to the aging brain."
        },
        {
            "id": "Neurology_Adams_8481",
            "title": "Neurology_Adams",
            "content": "Several pieces of evidence favor the view that elevation of the levels of A\u03b242 leads to aggregation of amyloid and then to neuronal toxicity. This is currently the most often cited hypothesis for the genesis of the disease. It appears that the diffuse deposition of A\u03b242 precedes the formation of better-defined neurofibrils and plaques."
        },
        {
            "id": "InternalMed_Harrison_30249",
            "title": "InternalMed_Harrison",
            "content": "FIGURE 448-4 Frontotemporal dementia syndromes are united by underlying frontotemporal lobar degeneration pathology, which can be divided according to the presence of tau, TPD-43, or FUS-containing inclusions in neurons and glia. Correlations between clinical syndromes and major molecular classes are shown with colored shading. Despite improvements in clinical syndromic diagnosis, a small percentage of patients with some frontotemporal dementia syndromes will show Alzheimer\u2019s disease neuropathology at autopsy (gray shading). aFTLD-U, atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions; AGD, argyrophilic grain disease; BIBD, basophilic inclusion body disease; bvFTD, behavioral variant frontotemporal dementia; CBD, corticobasal degeneration; CBS, corticobasal syndrome; CTE, chronic traumatic encephalopathy; FTD-MND, frontotemporal dementia with motor neuron disease; FTDP-17, frontotemporal dementia with parkinsonism linked to chromosome 17; FUS, fused in"
        },
        {
            "id": "InternalMed_Harrison_5418",
            "title": "InternalMed_Harrison",
            "content": "NEURODEGENERATIVE DISEASES: EXTENSION OF PRINCIPLE"
        },
        {
            "id": "Cell_Biology_Alberts_4726",
            "title": "Cell_Biology_Alberts",
            "content": "Figure 16\u201370 Two types of intermediate filaments in cells of the nervous system. Freeze-etch electron microscopic image of neurofilaments in a nerve cell axon, showing the extensive cross-linking through protein cross-bridges\u2014an arrangement believed to give this long cell process great tensile strength. The cross-bridges are formed by the long, nonhelical extensions at the C-terminus of the largest neurofilament protein (NF-H). (B) Freeze-etch image of glial filaments in glial cells, showing that these intermediate filaments are smooth and have few cross-bridges. Conventional transmission electron micrograph of a cross section of an axon showing the regular side-to-side spacing of the neurofilaments, which greatly outnumber the microtubules. (A and B, courtesy of Nobutaka Hirokawa; C, courtesy of John Hopkins.)"
        },
        {
            "id": "Neurology_Adams_8413",
            "title": "Neurology_Adams",
            "content": "It has been proposed that all degenerative diseases be classified according to their genetic and molecular abnormalities. However, when one notes the diversity of pathologic change that may accompany a single, seemingly unitary gene abnormality or, reciprocally, the diversity of genetic defects that may underlie a single phenotype, this type of classification does not prove immediately helpful to the clinician. In other words, the practice of creating new disease categories to encompass all the molecular and pathologic changes associated with a particular type of neuronal degeneration offers no great advantage in practice. For example, certain diseases are unified by the deposition of proteins and have been termed \u201ctauopathies,\u201d \u201csynucleinopathies,\u201d \u201camyloidopathies,\u201d and so forth. We endorse a more useful clinical approach that is based on an awareness of constellations of clinical features that relate to degeneration of specific neural systems. Until such time as the causation of"
        },
        {
            "id": "Cell_Biology_Alberts_4720",
            "title": "Cell_Biology_Alberts",
            "content": "directly control axonal diameter, which in turn influences how fast electrical signals travel down the axon. In addition, neurofilaments provide strength and stability to the long cell processes of neurons."
        },
        {
            "id": "Neurology_Adams_8488",
            "title": "Neurology_Adams",
            "content": "In recent years, some of the subcellular mechanisms that are deranged by the presence of intracellular or extracellular amyloid have been elucidated. The finding of a reduced number and enlargement of synapses in affected cortex early in the disease by DeKosky and Scheff and others could be interpreted as either the first sign of neuronal death or the result of the neuronal loss. Amyloid deposition would then be a later, secondary phenomenon. One hypothesis is that Alzheimer disease is a disorder of synaptic failure, as summarized by Querfurth and LaFerla. They summarize some of the subcellular derangements that may connect amyloid or tau deposition to neuronal cell loss; these include abnormal calcium regulation, inflammation, insulin signaling, cholesterol metabolism and aberrant cell-cycle reentry. These are complex and uncertain connections but they are among the most promising findings in this field of research."
        },
        {
            "id": "Neurology_Adams_8472",
            "title": "Neurology_Adams",
            "content": "in a nascent \u201cdiffuse\u201d form, without organization or core formation and then is appreciated mainly by immunohistochemical methods, as well as deposition in the walls of small blood vessels near the plaques, so-called congophilic angiopathy. (3) Granulovacuolar degeneration of neurons, most evident in the pyramidal layer of the hippocampus. This last change is least important in diagnosis but there is uncertainty regarding its nature; it had been thought to be simply a reactive process but recent studies suggest it reflects a defect in phagocytosis of degraded proteins."
        },
        {
            "id": "Neurology_Adams_8478",
            "title": "Neurology_Adams",
            "content": "Analyses of the plaques and neuronal fibrillary changes have been undertaken in an attempt to elucidate the mechanism of Alzheimer disease, but so far, to little avail beyond implicating one or both in the accompanying neuronal degeneration. Several histologic techniques assist in this endeavor, including refined methods for silver impregnation that stain both amyloid and its main constituent (beta-amyloid protein [A\u03b2]); immunostaining using antibodies specific to such proteins as ubiquitin, neuronal tau protein, and \u03b2-amyloid protein; and visualization of \u03b2-pleated protein sheets using thioflavine S and in the past especially, Congo red with ultraviolet and polarized light. Tau (composed chemically of \u03b22-transferrin) is a discrete cytoskeletal protein that promotes the assembly of microtubules, stabilizes their structure, and participates in synaptic plasticity in a yet to be defined manner. In the pathologic circumstances of Alzheimer disease, progressive supranuclear palsy, and one"
        },
        {
            "id": "InternalMed_Harrison_21938",
            "title": "InternalMed_Harrison",
            "content": "Light-chain deposits are not fibrillar and do not stain with Congo red, but they are easily detected with anti\u2013light chain antibody using immunofluorescence or as granular deposits on electron microscopy. A combination of the light chain rearrangement, self-aggregating properties at neutral pH, and abnormal metabolism probably contribute to the deposition. Treatment for light chain deposition disease is treatment of the primary disease and, if possible, autologous stem cell transplantation."
        },
        {
            "id": "Neurology_Adams_8752",
            "title": "Neurology_Adams",
            "content": "Postmortem examination of patients, originally reported by Rebeiz and colleagues, disclosed a combination of findings that differentiated the disease process from other neurodegenerative conditions. Cortical atrophy (mainly in the frontal motor\u2013premotor and anterior parietal lobes) was associated with degeneration of the substantia nigra and, in one instance, of the dentatorubrothalamic fibers. The loss of nerve cells was fairly marked, but there was no gross lobar atrophy, as occurs in Pick disease. The neuronal degeneration was more on one side of the brain than the other. There was moderate gliosis in the cortex and underlying white matter. The disease is now clearly considered to be related to tau deposition in specific brain structures; however, the original authors were more impressed with ballooned and chromatolytic neurons with eccentric nuclei, a state that was called neuronal achromasia. The presence of these achromatic cells in posterior frontal and parietal neurons"
        },
        {
            "id": "Histology_Ross_350",
            "title": "Histology_Ross",
            "content": "cells (mainly astrocytes; (GFAP) to lesser degree, ependymal cells), Schwann cells, enteric glial cells, satellite cells of sensory ganglia, and pituicytes Peripherin 54 Peripheral neurons Class 4: Neurofilaments Neuroflament L (NF-L) 68 Neurons Charcot-Marie-tooth disease Co-assembles with NF-M or NF-H Parkinson disease Neuroflament M (NF-M) 110 Neurons Co-assembles with NF-L Neuroflament H (NF-H) 130 Neurons Co-assembles with NF-L Nestin 240 Neural stem cells, some cells of neuroectodermal origin, muscle cells Co-assembles with desmin \u0391-Internexin 68 Neurons Synemin \u0391/\u0392A 182 Muscle cells Co-assembles with desmin Syncoilin 64 Muscle cells Paranemin 178 Muscle cells Co-assembles with desmin Class 5: Lamins Lamin A/CB 62\u201372 Nucleus of all nucleated cells Emery-Dreyfuss muscular dystrophy Lamin B 65\u201368 Nucleus of all nucleated cells Limb girdle muscular dystrophy Class 6: Beaded Filaments Phakinin (CP49)C 49 Eye lens fber cells Juvenile-onset cataracts Co-assembles with flesin"
        },
        {
            "id": "Histology_Ross_1723",
            "title": "Histology_Ross",
            "content": "perinuclear Golgi apparatus, lysosomes, microtubules, neurofilaments (intermediate filaments), transport vesicles, and inclusions (Fig. 12.4b). Nissl bodies, free ribosomes, and occasionally the Golgi apparatus extend into the dendrites but not into the axon. This area of the cell body, called the axon hillock, lacks large cytoplasmic organelles and serves as a landmark to distinguish between axons and dendrites in both light microscope and TEM preparations. The euchromatic nucleus, large nucleolus, prominent Golgi apparatus, and Nissl bodies indicate the high level of anabolic activity needed to maintain these large cells. Neurons do not divide; however, in some areas of the brain, neural stem cells are present and are able to differentiate and replace damaged nerve cells."
        },
        {
            "id": "Neurology_Adams_8427",
            "title": "Neurology_Adams",
            "content": "synucleinopathy, etc. Even this is an uncertain or intermediate classification as it is not known in most cases if the protein is the cause or the result of cellular damage, and in any case, the fundamental mechanisms of cellular destruction are still being determined."
        },
        {
            "id": "Neurology_Adams_8521",
            "title": "Neurology_Adams",
            "content": "the symptoms of dementia and parkinsonism are related to neurofibrillary changes in the cerebral cortex and substantia nigra, respectively; senile plaques and Lewy bodies are unusual findings. What can be deduced from the crossover syndromes is that multiple degenerative changes can occur in these diseases and give rise to heterogeneity in clinical presentation."
        },
        {
            "id": "Neurology_Adams_119",
            "title": "Neurology_Adams",
            "content": "demonstration of several discrete (oligoclonal) electrophoretic \u201cbands,\u201d each representing a specific immune globulin, and the ratio of IgG to total protein, are of special diagnostic importance in multiple sclerosis, as discussed in Chap. 36."
        },
        {
            "id": "InternalMed_Harrison_30248",
            "title": "InternalMed_Harrison",
            "content": "The toxicity and spreading capacity of tau aggregates underlies the pathogenesis of many familial cases and is emerging as a key factor in sporadic tauopathies, although loss of tau microtubule stabilizing function may also play a role. TDP-43 and FUS, in contrast, are RNA/ DNA binding proteins whose roles in neuronal function are still being actively investigated, but one key role may be the chaperoning of Pick\u2019s 3R tau FTDP-17 MAPTOther: CTE, AGD, MST, GGT CBD 4R tau PSP 4R tau aFTLD-U BIBD NIFID/ NIBD FUS NOS FUSType U (C9ORF72)(TARDBP)Type D VCPType A (PGRN)(C9ORF72)Type B (C9ORF72)Type C Alzheimer\u2019s disease bvFTD svPPA nfvPPA FTD-MND CBS PSPS FTLD-tau FTLD-TDP* FTLD-FUS FTLD-3 CHMP2BFrontotemporal lobar degeneration (FTLD)"
        }
    ],
    "scores": [
        0.026375404530744335,
        0.025461663235385866,
        0.025199073148355074,
        0.023989257889976676,
        0.02191104147625887,
        0.019801980198019802,
        0.019547691478146098,
        0.018978233495232956,
        0.018883049790683174,
        0.01846494213750851,
        0.01711081986311344,
        0.01685159500693481,
        0.016817410966647822,
        0.015968310948814755,
        0.01588901405110571,
        0.0156981039152918,
        0.01554001554001554,
        0.015396368337544809,
        0.015369890778065533,
        0.015268065268065269,
        0.014770023790642347,
        0.014578288942695722,
        0.014216843762298308,
        0.014206712433257055,
        0.013586592178770951,
        0.013480392156862746,
        0.013413547237076648,
        0.013303378705783886,
        0.013277826468010517,
        0.012740133429788601,
        0.012719106482769586,
        0.012593762337149626
    ]
}